Rise of sodium-glucose cotransporter 2 inhibitors in the management of nonalcoholic fatty liver disease
Non-alcoholic fatty liver disease (NAFLD) is the most common form of chronic liver disease in the Western world. It is more prevalent in male gender, and with increasing age, obesity, and insulin resistance. Besides weight loss, there are limited treatment options. The use of anti-diabetic medications has been studied with mixed results. In this review, we discuss the use of anti-diabetic medications in the management of NAFLD with a specific focus on sodium-glucose cotransporter 2 inhibitors. We shed light on the evidence supporting their use in detail and discuss limitations and future directions.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
World journal of hepatology - 11(2019), 7 vom: 27. Juli, Seite 562-573 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dokmak, Amr [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Diabetes |
|---|
| Anmerkungen: |
Date Revised 01.10.2020 published: Print Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.4254/wjh.v11.i7.562 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM299991814 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM299991814 | ||
| 003 | DE-627 | ||
| 005 | 20231225101538.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4254/wjh.v11.i7.562 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0999.xml |
| 035 | |a (DE-627)NLM299991814 | ||
| 035 | |a (NLM)31388398 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dokmak, Amr |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Rise of sodium-glucose cotransporter 2 inhibitors in the management of nonalcoholic fatty liver disease |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 01.10.2020 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Non-alcoholic fatty liver disease (NAFLD) is the most common form of chronic liver disease in the Western world. It is more prevalent in male gender, and with increasing age, obesity, and insulin resistance. Besides weight loss, there are limited treatment options. The use of anti-diabetic medications has been studied with mixed results. In this review, we discuss the use of anti-diabetic medications in the management of NAFLD with a specific focus on sodium-glucose cotransporter 2 inhibitors. We shed light on the evidence supporting their use in detail and discuss limitations and future directions | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Diabetes | |
| 650 | 4 | |a Liver cirrhosis | |
| 650 | 4 | |a Non-alcoholic fatty liver disease | |
| 650 | 4 | |a Non-alcoholic steatohepatitis | |
| 650 | 4 | |a Sodium-glucose cotransporter 2 inhibitors | |
| 700 | 1 | |a Almeqdadi, Mohammad |e verfasserin |4 aut | |
| 700 | 1 | |a Trivedi, Hirsh |e verfasserin |4 aut | |
| 700 | 1 | |a Krishnan, Sandeep |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t World journal of hepatology |d 2009 |g 11(2019), 7 vom: 27. Juli, Seite 562-573 |w (DE-627)NLM204379024 |x 1948-5182 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2019 |g number:7 |g day:27 |g month:07 |g pages:562-573 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4254/wjh.v11.i7.562 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2019 |e 7 |b 27 |c 07 |h 562-573 | ||